Formulations & Dosing in Gender-Affirming Care
Injectable, Transdermal, and Other Testosterone Regimens, and How Targets Differ from Hypogonadism TRT
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Off-label; products used are the same FDA-approved testosterone esters/gels labeled for male hypogonadism
- WADA
- Prohibited (S1 Anabolic Agent) in sport
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about formulations & dosing in gender-affirming care in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Gender-affirming testosterone uses the same FDA-approved formulations as male hypogonadism therapy, injectable testosterone cypionate or enanthate, transdermal gels and patches, and (less commonly in this setting) long-acting testosterone undecanoate or subcutaneous pellets. The most common regimen historically is intramuscular or subcutaneous cypionate/enanthate, often ~50-100 mg weekly or equivalent, titrated to a typical adult male total testosterone range. The target differs from TRT not in the number per se but in intent: producing masculinization, with dose individualized to goals (including lower-dose 'microdosing' for some nonbinary people) and guided by trough levels and clinical response per Endocrine Society and WPATH monitoring schedules.
Same molecules as TRT, different aim: titrate to a typical male range and to the masculinization the patient wants.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
Microdosing and the spectrum of goals
Unlike TRT, which has a single conceptual target (replace what's missing), gender-affirming dosing spans a spectrum. Some patients want full, rapid virilization; some nonbinary patients want only selected changes (e.g., voice and body composition) and use deliberately low doses, accepting slower and incomplete masculinization. This goal-driven titration is a defining feature absent from deficiency-based TRT and is reflected in SOC-8's emphasis on individualized care.
How it is taken
Regimens are individualized. A common approach is testosterone cypionate or enanthate by subcutaneous or intramuscular injection, frequently in the ~50-100 mg weekly range, titrated by trough total testosterone and clinical response toward a typical adult male window. Transdermal gels and patches suit those preferring to avoid injections, accepting steadier but sometimes lower levels and the need for daily use. Long-acting undecanoate reduces injection frequency. Nonbinary patients may use deliberately lower 'microdoses' to achieve partial, slower masculinization. SOC-8 and the Endocrine Society favor titration to range and clinical effect rather than maximizing levels.
Safety in detail
This intervention requires evaluation, dosing, and monitoring by a qualified clinician. Self-dosing or unmonitored escalation carries documented risks. Standard products are prescription medications.
Replacement is not the same as a cycle
Gender-affirming testosterone is intended to keep levels within a typical adult male physiological range. Levels pushed supraphysiologically (whether by self-administration, dose-stacking, or chasing faster results) carry the same risks documented for anabolic excess, erythrocytosis, adverse lipid shifts, and uncertain cardiovascular consequences, without proportional masculinizing benefit. Physiological masculinization, not anabolic excess, is the clinical goal.
What it does to fertility
All effective masculinizing doses suppress ovulation and menses but are not contraceptive; fertility-preservation counseling should precede initiation regardless of formulation.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Trough total testosterone titrated to a typical male range
- Hematocrit/hemoglobin
- Lipid panel
- Clinical assessment of masculinization and side effects
What people get wrong
Often saidHigher doses masculinize faster and better
ActuallyBeyond a typical male range, higher doses mainly increase risks (erythrocytosis, lipid and possible cardiovascular effects, more aromatization to estradiol) without reliably accelerating the permanent changes. Guidelines target a normal range, not supraphysiological levels.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
The key difference from hypogonadism TRT is conceptual, not pharmacologic: the molecules and approved products are identical, but in gender-affirming care the clinician titrates to induce a new phenotype toward a typical male range, whereas TRT restores a deficient male to his prior baseline. Both avoid supraphysiological excess; gender-affirming care additionally accommodates microdosing for partial goals, which has no real analogue in deficiency-correction TRT.
At a glance
- Common first-line
- IM or subcutaneous testosterone cypionate/enanthate
- Typical injectable dose
- Roughly 50-100 mg/week or equivalent (individualized)
- Transdermal option
- Testosterone gel 1%/1.62% or patch (steadier levels, more application demand)
- Long-acting option
- Testosterone undecanoate (less frequent dosing)
- Target
- Typical adult male total T range, titrated to goals
- Microdosing
- Lower doses used by some nonbinary patients for partial effect
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Formulations & Dosing in Gender-Affirming Care. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.